RhoVac Marketed in International Press
STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...
First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany
STOCKHOLM, April 24, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The first patient in Germany is in treatment...
Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding
STOCKHOLM, April 2, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, onApril 2 2020, that the company is now seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic. However, the company believes that ...
RhoVac Announces Appointment of Professor Anne J. Ridley to its Scientific Advisory Board
STOCKHOLM, Feb. 6, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 6 th February 2020, the appointment of a leading oncology expert to its Scientific Advisory Board with the addition ofAnne J. Ridley, PhD, Professor of Cell Biology and Head of School of Cellular and Molecular Medicine, ...
RhoVac Reports Interim Results on Immunological Response with RV001
STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- Today, 18th November 2019, RhoVac AB ("RhoVac") reports interim results from ongoing immunological studies at University of Tübingen,Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells. In July 2019 RhoVac publishe...
